Cargando…

Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges

Malignant tumors remain the health problem of highest concern among people worldwide due to its high mortality and recurrence. Lung, gastric, liver, colon, and breast cancers are among the top five malignant tumors in terms of morbidity and mortality. In cancer biology, aberrant signaling pathway re...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Hongdan, Shao, Xiaoni, Li, Yanan, Gihu, Ribu, Xie, Haochen, Zhou, Junfu, Yan, Hengxiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203325/
https://www.ncbi.nlm.nih.gov/pubmed/34135756
http://dx.doi.org/10.3389/fphar.2021.675675
_version_ 1783708148149780480
author He, Hongdan
Shao, Xiaoni
Li, Yanan
Gihu, Ribu
Xie, Haochen
Zhou, Junfu
Yan, Hengxiu
author_facet He, Hongdan
Shao, Xiaoni
Li, Yanan
Gihu, Ribu
Xie, Haochen
Zhou, Junfu
Yan, Hengxiu
author_sort He, Hongdan
collection PubMed
description Malignant tumors remain the health problem of highest concern among people worldwide due to its high mortality and recurrence. Lung, gastric, liver, colon, and breast cancers are among the top five malignant tumors in terms of morbidity and mortality. In cancer biology, aberrant signaling pathway regulation is a prevalent theme that drives the generation, metastasis, invasion, and other processes of all malignant tumors. The Wnt/β-catenin, PI3K/AKT/mTOR, Notch and NF-kB pathways are widely concerned and signal crosstalks exist in the five solid tumors. This review provides an innovative summary of the recent progress in research on these signaling pathways, the underlying mechanism of the molecules involved in these pathways, and the important role of some miRNAs in tumor-related signaling pathways. It also presents a brief review of the antitumor molecular drugs that target these signaling pathways. This review may provide a theoretical basis for the study of the molecular biological mechanism of malignant tumors and vital information for the development of new treatment strategies with a focus on efficacy and the reduction of side effects.
format Online
Article
Text
id pubmed-8203325
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82033252021-06-15 Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges He, Hongdan Shao, Xiaoni Li, Yanan Gihu, Ribu Xie, Haochen Zhou, Junfu Yan, Hengxiu Front Pharmacol Pharmacology Malignant tumors remain the health problem of highest concern among people worldwide due to its high mortality and recurrence. Lung, gastric, liver, colon, and breast cancers are among the top five malignant tumors in terms of morbidity and mortality. In cancer biology, aberrant signaling pathway regulation is a prevalent theme that drives the generation, metastasis, invasion, and other processes of all malignant tumors. The Wnt/β-catenin, PI3K/AKT/mTOR, Notch and NF-kB pathways are widely concerned and signal crosstalks exist in the five solid tumors. This review provides an innovative summary of the recent progress in research on these signaling pathways, the underlying mechanism of the molecules involved in these pathways, and the important role of some miRNAs in tumor-related signaling pathways. It also presents a brief review of the antitumor molecular drugs that target these signaling pathways. This review may provide a theoretical basis for the study of the molecular biological mechanism of malignant tumors and vital information for the development of new treatment strategies with a focus on efficacy and the reduction of side effects. Frontiers Media S.A. 2021-05-31 /pmc/articles/PMC8203325/ /pubmed/34135756 http://dx.doi.org/10.3389/fphar.2021.675675 Text en Copyright © 2021 He, Shao, Li, Gihu, Xie, Zhou and Yan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
He, Hongdan
Shao, Xiaoni
Li, Yanan
Gihu, Ribu
Xie, Haochen
Zhou, Junfu
Yan, Hengxiu
Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
title Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
title_full Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
title_fullStr Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
title_full_unstemmed Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
title_short Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
title_sort targeting signaling pathway networks in several malignant tumors: progresses and challenges
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203325/
https://www.ncbi.nlm.nih.gov/pubmed/34135756
http://dx.doi.org/10.3389/fphar.2021.675675
work_keys_str_mv AT hehongdan targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges
AT shaoxiaoni targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges
AT liyanan targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges
AT gihuribu targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges
AT xiehaochen targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges
AT zhoujunfu targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges
AT yanhengxiu targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges